Company Filing History:
4 out of 4,177 
1 out of 7 Years Active: 2013-2018
Title: Wang Sheng: Innovator in Cancer Treatment and Hybrid Computing
Introduction
Wang Sheng is a prominent inventor based in Beijing, China. He has made significant contributions to the fields of cancer treatment and hybrid computing. With a total of 5 patents, his work has garnered attention for its innovative approaches and practical applications.
Latest Patents
Wang Sheng's latest patents include a quinazoline heterocyclic compound as an EGFR kinase inhibitor. This invention relates to specific compounds that can be used to treat or prevent various cancer diseases by targeting the epidermal growth factor receptor (EGFR), including some mutant forms of EGFR. Another notable patent involves systems and methods for communicating and switching between components in a hybrid computing environment. This system is designed to maintain continuity of settings when switching between different operating platforms, enhancing user experience and efficiency.
Career Highlights
Throughout his career, Wang Sheng has worked with notable companies such as Lenovo Pte. Ltd. and Beijing Scitech-MQ Pharmaceuticals Limited. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in technology and healthcare.
Collaborations
Wang Sheng has collaborated with esteemed professionals in his field, including Steven Richard Perrin and Scott Edwards Kelso. These partnerships have facilitated the exchange of ideas and fostered innovation in his projects.
Conclusion
Wang Sheng's contributions to cancer treatment and hybrid computing exemplify the impact of innovation in addressing complex challenges. His patents reflect a commitment to advancing technology for the betterment of society.